Baxter International (NYSE:BAX) Price Target Lowered to $22.00 at Evercore

Baxter International (NYSE:BAX) had its price objective decreased by stock analysts at Evercore from $23.00 to $22.00 in a research note issued to investors on Monday,MarketScreener reports. The firm currently has an “outperform” rating on the medical instruments supplier’s stock. Evercore’s price objective indicates a potential upside of 33.52% from the company’s current price.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Baxter International in a research report on Wednesday, January 21st. Zacks Research upgraded shares of Baxter International from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Wells Fargo & Company reduced their target price on Baxter International from $21.00 to $19.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Jefferies Financial Group decreased their target price on Baxter International from $21.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, February 13th. Finally, Citigroup reduced their price target on shares of Baxter International from $21.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Baxter International currently has an average rating of “Hold” and a consensus target price of $19.80.

Baxter International Stock Performance

BAX stock opened at $16.48 on Monday. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.56 and a current ratio of 2.31. Baxter International has a 52 week low of $15.73 and a 52 week high of $32.68. The firm has a 50 day simple moving average of $18.93 and a 200 day simple moving average of $19.75. The stock has a market cap of $8.51 billion, a P/E ratio of -8.93, a P/E/G ratio of 1.18 and a beta of 0.62.

Baxter International (NYSE:BAX) last issued its earnings results on Thursday, February 12th. The medical instruments supplier reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.09). Baxter International had a negative net margin of 8.51% and a positive return on equity of 16.95%. The firm had revenue of $2.97 billion during the quarter, compared to analyst estimates of $2.82 billion. During the same quarter in the previous year, the company posted $0.58 earnings per share. The business’s revenue for the quarter was up 8.0% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.850-2.050 EPS. Research analysts anticipate that Baxter International will post 2.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Baxter International

Several large investors have recently added to or reduced their stakes in the stock. Basepoint Wealth LLC purchased a new position in Baxter International in the 4th quarter worth $26,000. CoreFirst Bank & Trust purchased a new position in shares of Baxter International in the second quarter worth about $27,000. Imprint Wealth LLC acquired a new stake in shares of Baxter International during the third quarter worth about $27,000. CYBER HORNET ETFs LLC purchased a new stake in Baxter International in the second quarter valued at approximately $40,000. Finally, MUFG Securities EMEA plc purchased a new stake in Baxter International in the second quarter valued at approximately $46,000. 90.19% of the stock is owned by hedge funds and other institutional investors.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.